Percutaneous balloon mitral valvotomy sustained significant improvements in NYHA class, mitral valve area, and hemodynamics over 6 years in 90 patients with rheumatic mitral stenosis.
Does percutaneous balloon mitral valvotomy (PBMV) improve long-term clinical and hemodynamic outcomes in patients with rheumatic mitral stenosis?
PBMV provides sustained clinical and hemodynamic benefits up to 6 years in patients with rheumatic mitral stenosis.
Absolute Event Rate: 0% vs 0%
ABSTRACT Background Analysis of the long‐term effects of percutaneous balloon mitral valvotomy (PBMV) intervention in patients with rheumatic mitral stenosis. Aims To evaluate the long‐term efficacy, safety, and hemodynamic outcomes of PBMV in patients with rheumatic heart disease and mitral stenosis through a 6‐year retrospective clinical follow‐up. Methods Ninety patients with rheumatic mitral stenosis treated in our hospital from January 2012 to 2017 were selected retrospectively. The changes of cardiac function grade before and 1, 3, and 6 years after intervention, left atrial diameter (LADd), mitral valve area (MVA), transvalvular pressure difference (MVG), pulmonary artery systolic pressure (PAPs), left ventricular ejection fraction (LVEF), and restenosis 1, 3, and 6 years after intervention were observed. Results Post‐procedural NYHA functional class improved significantly compared with baseline ( p 0.05). Conclusions The long‐term effect of PBMV is good in patients with rheumatic mitral stenosis.
Xu et al. (Tue,) reported a other. Percutaneous balloon mitral valvotomy sustained significant improvements in NYHA class, mitral valve area, and hemodynamics over 6 years in 90 patients with rheumatic mitral stenosis.